Evidence map›Paper›PMID 37987169›Full record

ArticleJournal of cell science2023

Cell jamming in a collagen-based interface assay is tuned by collagen density and proteolysis.

Lianne Beunk, Nan Wen, Sjoerd van Helvert, Bram Bekker, Lars Ran, Ross Kang, Tom Paulat, Simon Syga, Andreas Deutsch, Peter Friedl and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cell science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Amoeboid-mesenchymal transition and the proteolytic control of cancer invasion plasticity.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Lianne BeunkDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands.ORCID 0000-0002-3524-1520
Nan WenDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands.ORCID 0000-0002-7637-1209
Sjoerd van HelvertDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands.ORCID 0000-0002-4958-9819
Bram BekkerDepartment of Mathematics, Faculty of Natural Science, Mathematics and Informatics, Radboud University, 6500 GL Nijmegen, The Netherlands.
Lars RanDepartment of Mathematics, Faculty of Natural Science, Mathematics and Informatics, Radboud University, 6500 GL Nijmegen, The Netherlands.
Ross KangDepartment of Mathematics, Faculty of Natural Science, Mathematics and Informatics, Radboud University, 6500 GL Nijmegen, The Netherlands.ORCID 0000-0002-4219-593X
Tom PaulatDepartment of Innovative Computing, Centre for Information Services and High Performance Computing, Technical University Dresden, 01062 Dresden, Germany.
Simon SygaDepartment of Innovative Computing, Centre for Information Services and High Performance Computing, Technical University Dresden, 01062 Dresden, Germany.ORCID 0000-0001-9955-9012
Andreas DeutschDepartment of Innovative Computing, Centre for Information Services and High Performance Computing, Technical University Dresden, 01062 Dresden, Germany.ORCID 0000-0002-9005-6897
Peter FriedlDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands.ORCID 0000-0002-0119-4041
Katarina WolfDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands.ORCID 0000-0003-0616-2708
Radboud University Nijmegen · NLTechnische Universität Dresden · DEThe University of Texas MD Anderson Cancer Center · US

Funding

China Scholarship Council 202206240025Deutsche Krebshilfe 70112014European Social FundNederlandse Organisatie voor Wetenschappelijk Onderzoek OCENW.GROOT 2019.022Radboud Institute for Molecular Life SciencesRadboud Universiteit
6 · The paper itself

Abstract

Tumor cell invasion into heterogenous interstitial tissues consisting of network-, channel- or rift-like architectures involves both matrix metalloproteinase (MMP)-mediated tissue remodeling and cell shape adaptation to tissue geometry. Three-dimensional (3D) models composed of either porous or linearly aligned architectures have added to the understanding of how physical spacing principles affect migration efficacy; however, the relative contribution of each architecture to decision making in the presence of varying MMP availability is not known. Here, we developed an interface assay containing a cleft between two high-density collagen lattices, and we used this assay to probe tumor cell invasion efficacy, invasion mode and MMP dependence in concert. In silico modeling predicted facilitated cell migration into confining clefts independently of MMP activity, whereas migration into dense porous matrix was predicted to require matrix degradation. This prediction was verified experimentally, where inhibition of collagen degradation was found to strongly compromise migration into 3D collagen in a density-dependent manner, but interface-guided migration remained effective, occurring by cell jamming. The 3D interface assay reported here may serve as a suitable model to better understand the impact of in vivo-relevant interstitial tissue topologies on tumor invasion patterning and responses to molecular interventions.

Indexed as

CollagenExtracellular MatrixCell MovementHumansNeoplasm InvasivenessProteolysisCollagenCell jammingCell migrationCollagen–collagen cleft modelECM-directed proteolysisLinear confinementTumor spheroid

Identifiers

PMID37987169
PMCPMC10753497
OpenAlexW4388846986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.